Q1 | Q2 | Q3 | Q4 | P | |
---|---|---|---|---|---|
(n = 142) | (n = 142) | (n = 142) | (n = 141) | ||
Primary Outcome | |||||
POPF, n (%) | 29 (20.42%) | 29 (20.42%) | 22 (15.49%) | 28 (19.86%) | |
OR95%CI | 1 | 1 (0.56,1.78) | 0.71 (0.39,1.32) | 0.97 (0.54,1.73) | 0.668 |
Adjusted OR95%CI† | 1 | 1.15 (0.62,2.11) | 0.86 (0.45,1.63) | 1.3 (0.69,2.46) | 0.618 |
Secondary Outcomes | |||||
Grade B POPF, n (%) | 21 (14.79%) | 24 (16.90%) | 15 (10.56%) | 20 (14.18%) | |
Adjusted OR95%CI† | 1 | 1.38 (0.7,2.72) | 0.92 (0.44,1.92) | 1.31 (0.63,2.7) | 0.62 |
Grade C POPF, n (%) | 11 (7.75%) | 4 (2.82%) | 5 (3.5%) | 8 (5.63%) | |
Adjusted OR95%CI† | 1 | 0.68 (0.22,2.08) | 0.73 (0.23,2.27) | 1.25 (0.42,3.69) | 0.698 |
BL, n (%) | 7 (4.9%) | 5 (3.5%) | 7 (4.9%) | 6 (4.3%) | |
Adjusted OR95%CI† | 1 | 0.61 (0.18,2.02) | 0.99 (0.33,2.98) | 0.95 (0.29,3.06) | 0.841 |
PPH, n (%) | 27 (19%) | 29 (20.40%) | 25 (17.60%) | 37 (26.20%) | |
Adjusted OR95%CI† | 1 | 1.15 (0.62,2.12) | 0.97 (0.52,1.81) | 1.86 (1.01,3.43) | 0.115 |
DGE, n (%) | 24 (16.90%) | 14 (9.90%) | 22 (15.50%) | 24 (17.00%) | |
Adjusted OR95%CI† | 1 | 0.55 (0.27,1.13) | 0.99 (0.51,1.89) | 1.22 (0.63,2.36) | 0.187 |